Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Schuind

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Vaccine|June 8, 2007
Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataKatrin S Kohl, Wikke Walop, Jane Gidudu, et al.
Vaccine|October 28, 2008
A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataJane Gidudu, Katrin S Kohl, Scott Halperin, et al.
Drug Safety|June 11, 2021
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six TrialsMarta López-Fauqued, Maribel Co-van der Mee, Adriana Bastidas, et al.
Human Vaccines & Immunotherapeutics|February 21, 2020
Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US childrenAmber Hsiao, Philip O Buck, Arnold Yee, et al.
Vaccine|February 12, 2017
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trialAnuradha Madan, Murdo Ferguson, Eric Sheldon, et al.
Vaccine|September 21, 2019
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trialsDavid O Willer, Lidia Oostvogels, Anthony L Cunningham, et al.
Journal of the Pediatric Infectious Diseases Society|November 15, 2019
Evaluation of a New Clinical Endpoint for Moderate to Severe Influenza Disease in Children: A Prospective Cohort StudySuchitra Rao, Emad Yanni, Angela Moss, et al.
Vaccine|June 9, 2023
Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling studyValerian Mwenda, Rose Jalang'o, Christine Miano, et al.
Human Vaccines & Immunotherapeutics|April 30, 2020
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trialsRomulo Colindres, Valentine Wascotte, Alain Brecx, et al.
Vaccine|June 2, 2007
Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataKatrin S Kohl, Leslie Ball, Jane Gidudu, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Vaccine|June 8, 2007
Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataKatrin S Kohl, Wikke Walop, Jane Gidudu, et al.
Vaccine|October 28, 2008
A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataJane Gidudu, Katrin S Kohl, Scott Halperin, et al.
Drug Safety|June 11, 2021
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six TrialsMarta López-Fauqued, Maribel Co-van der Mee, Adriana Bastidas, et al.
Human Vaccines & Immunotherapeutics|February 21, 2020
Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US childrenAmber Hsiao, Philip O Buck, Arnold Yee, et al.
Vaccine|February 12, 2017
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trialAnuradha Madan, Murdo Ferguson, Eric Sheldon, et al.
Vaccine|September 21, 2019
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trialsDavid O Willer, Lidia Oostvogels, Anthony L Cunningham, et al.
Journal of the Pediatric Infectious Diseases Society|November 15, 2019
Evaluation of a New Clinical Endpoint for Moderate to Severe Influenza Disease in Children: A Prospective Cohort StudySuchitra Rao, Emad Yanni, Angela Moss, et al.
Vaccine|June 9, 2023
Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling studyValerian Mwenda, Rose Jalang'o, Christine Miano, et al.
Human Vaccines & Immunotherapeutics|April 30, 2020
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trialsRomulo Colindres, Valentine Wascotte, Alain Brecx, et al.
Vaccine|June 2, 2007
Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataKatrin S Kohl, Leslie Ball, Jane Gidudu, et al.
Pageof 6